Zhonghui Bio-B

Zhonghui Bio is a clinical-stage biopharmaceutical company based in China, specializing in the development of innovative therapies for autoimmune and inflammatory diseases. The company's lead candidate is a monoclonal antibody targeting Interleukin-17A, currently in Phase 3 clinical trials for the treatment of moderate-to-severe plaque psoriasis. Beyond its lead program, Zhonghui Bio is advancing a diverse pipeline of biologics, including bispecific antibodies and recombinant proteins, aimed at addressing significant unmet needs in respiratory and dermatological conditions. The company leverages its internal R&D capabilities to develop high-quality biologics that are competitive in both domestic and global markets.